Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies

Journal of Allergy and Clinical Immunology

Volumn 119, Issue 4, 2007, Pages 1005-1011

  von Gunten, Stephan ^a   Vogel, Monique ^b   Schaub, Alexander ^b   Stadler, Beda M ^b   Miescher, Sylvia ^b,c   Crocker, Paul R ^d   Simon, Hans Uwe ^a  

^a Departments of Pharmacology   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c ZLB Behring AG   (Switzerland)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Apoptosis; autoantibodies; eosinophils; inflammation; IVIg; Siglec 8

Indexed keywords

AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 5; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; EOSINOPHIL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; APOPTOSIS; AUTOANTIBODIES; CELL DEATH; CELLS, CULTURED; EOSINOPHILS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPEREOSINOPHILIC SYNDROME; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-5; LECTINS; LEPTIN;

EID: 34047161745     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.01.023     Document Type: Article

References (26)

1. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
2. Simon H.U., and Späth P.J. IVIG-mechanisms of action. Allergy 58 (2003) 543-552
3. Jolles S., Sewell W.A., and Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142 (2005) 1-11
4. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
5. Altznauer F., von Gunten S., Späth P., and Simon H.U. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 112 (2003) 1185-1190
6. von Gunten S., Schaub A., Vogel M., Stadler B.M., Miescher S., and Simon H.U. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 (2006) 4255-4259
7. Nutku E., Aizawa H., Hudson S.A., and Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101 (2003) 5014-5020
8. Nutku E., Hudson S.A., and Bochner B.S. Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem Biophys Res Commun 336 (2005) 918-924
9. von Gunten S., Yousefi S., Seitz M., Jakob S.M., Schaffner T., Seger R., et al. Siglec-9 transduces apoptotic and non-apoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment. Blood 106 (2005) 1423-1431
10. Simon H.U., Weber M., Becker E., Zilberman Y., Blaser K., and Levi-Schaffer F. Eosinophils maintain their capacity to signal and release eosinophilic cationic protein upon repetitive stimulation with the same agonist. J Immunol 165 (2000) 4069-4075
11. Simon H.U., Plötz S., Simon D., Seitzer U., Braathen L.R., Menz G., et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 33 (2003) 834-839
12. Vassina E.M., Yousefi S., Simon D., Zwicky C., Conus S., and Simon H.U. cIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol 36 (2006) 1975-1984
13. Floyd H., Ni J., Cornish A., Zeng Z., Liu D., Carter K., et al. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem 275 (2000) 861-866
14. Baumann R., Casaulta C., Simon D., Conus S., Yousefi S., and Simon H.U. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB J 17 (2003) 2221-2230
15. Yousefi S., Hoessli D., Blaser K., Mills G., and Simon H.U. Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 183 (1996) 1407-1414
16. Yousefi S., Perozzo R., Schmid I., Ziemiecki A., Schaffner T., Scapozza L., et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nature Cell Biol 8 (2006) 1124-1132
17. Altznauer F., Martinelli S., Yousefi S., Thürig C., Schmid I., Conway E.M., et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 199 (2004) 1343-1354
18. Conus S., Bruno A., and Simon H.U. Leptin is an eosinophil survival factor. J Allergy Clin Immunol 116 (2005) 1228-1234
19. Plötz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
20. Simon H.U. Molecules involved in the regulation of eosinophil apoptosis. Chem Immunol Allergy 91 (2006) 49-58
21. Simon H.U., Haj-Yehia A., and Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5 (2000) 415-418
22. Mollnes T., Brekke O., Fung M., Fure H., Christiansen D., Bergseth G., et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002) 1869-1877
23. Bochner B.S., Alvarez R.A., Mehta P., Bovin N.V., Blixt O., White J.R., et al. Glycan array screening reveals a candidate ligand for Siglec-8. J Biol Chem 280 (2005) 4307-4312
24. Klion A., Bochner B.S., Gleich G., Nutman T., Rothenberg M., Simon H.U., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
25. Takigawa N., Kawata N., Shibayama T., Tada A., Kimura G., Munemasa M., et al. Successful treatment of a patient with severe Churg-Strauss syndrome by a combination of pulse corticosteroids, pulse cyclophosphamide, and high-dose intravenous immunoglobulin. J Asthma 42 (2005) 639-641
26. Tsurikisawa N., Taniguchi M., Saito H., Himeno H., Ishibashi A., Suzuki S., et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92 (2004) 80-87